Thermo Fisher Scientific BCL9L Polyclonal Antibody

Applications

Immunocytochemistry (ICC/IF)

• Tested Dilution: 0.25–2 µg/mL

Product Specifications

Product Specific Information

Immunogen sequence:
MGMEFGGGRG LLSPPMGQSG LREVDPPMGP GNLNMNMNVN MNMNMNLNVQ MTPQQQMLMS QKMRGPGDLM GPQGLSPEEM ARVRAQNSSG VMGGPQKMLM P

Target Information

Bcl9L, a homolog of Bcl9, was initially identified through bioinformatics screening. It is expressed in fetal brain, adult lung, eye, and prostate, as well as in several tumor types including pancreatic and prostate cancers.
Bcl9L interacts with beta-catenin, a target of the Wnt signaling pathway, and is required for enhanced beta-catenin–T-cell factor (TCF)-mediated transcription in colorectal tumor cells, possibly by translocating beta-catenin to the nucleus.
Studies indicate that Bcl9L expression correlates with high nuclear grade cancer phenotype and ErbB2/HER-2 expression in breast cancers, suggesting activity in other cancer types.
Bcl9L is also critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas associated with tumor invasion, metastasis, and therapy resistance.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.